ArticleTransboundary and emerging diseases2025
Safety of Live Attenuated ASFV-G-ΔI177L/ΔLVR Vaccination in Sows With Advanced Pregnancies.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Evaluation of the vaccine candidate ASFV-MEC-01: safety, efficacy, transmission dynamics, and assessment of reversion to virulence.Emerging microbes & infections · 2026Article
- Live-attenuated African swine fever vaccine HLJ/18-7GD is safe in pregnant sows with no impact on reproductive performance or offspring health at a field farm.Emerging microbes & infections · 2026Article
- Article
- Article
- The Prospects and Challenges of Live Attenuated Vaccines Against African Swine Fever Virus in Vietnam.Vaccines · 2026Review
- Implications for safety:Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) causes severe disease in domestic pigs and wild boars and often results in 100% mortality. The use of attenuated strains in ASF vaccine development, based on the most recently studied ASF virus (ASFV)-Georgia (ASFV-G) strain, has proven effective. In July 2023, Vietnam became the first country in the world to have two indigenously developed ASF vaccines approved for commercial sale locally. In this study, we evaluated the immunogenicity and safety of the live attenuated vaccine (LAV) ASFV-G-ΔI177L/ΔLVR derived from ASFV-G-ΔI177L in five pregnant sows and a control group. The ASFV-G-ΔI177L replicates efficiently in a stable swine cell line. Therefore, the pregnant sows were used to validate the vaccine. Fundamental assessments of clinical symptoms (vaccine safety), parturition performance, vertical transmission presence after birth, and maternal antibodies were conducted before and after colostrum intake following the vaccination with ASF-G-ΔI177L/ΔLVR. The vaccination had no adverse effects and induced a high level of antibody production. Normal delivery was also confirmed without miscarriages. Furthermore, ASF antibodies and the P72 gene were detected in the blood of most piglets that consumed colostrum from vaccinated sows, and transplacental transmission was confirmed in piglets following vaccination. While these results will influence vaccine development and play an important role in preventing lethal ASFV infections, they also highlight the potential of ASFV-G-ΔI177L/ΔLVR to protect even high-risk groups such as pregnant sows and emphasize the importance of continued vigilance and investigation of vaccine safety parameters such as viral shedding, genetic stability, and reproductive efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.